Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors

European Journal of Pharmacology

Volumn 632, Issue 1-3, 2010, Pages 45-51

  Liu, Cui Qing ^a,b,c   Wong, Siu Ling ^c   Leung, Fung Ping ^c   Tian, Xiao Yu ^c   Lau, Chi Wai ^c   Lu, Limin ^b   Yao, Xiaoqiang ^c   Chen, Zhen Yu ^c   Yao, Tai ^b   Huang, Yu ^c  

^a HANGZHOU NORMAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

(Rat); Artery; Cyclic AMP; Phosphodiesterase; Prostanoid TP receptor; Relaxation

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CILOSTAZOL; CYCLIC AMP; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID RECEPTOR; PROTEIN KINASE C INHIBITOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROLIPRAM; T 0156; TERUTROBAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; VASODILATATION; WESTERN BLOTTING;

EID: 77349086101     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.008     Document Type: Article

References (30)

1. + channels of vascular smooth muscle cells. Am. J. Physiol. 275 (1998) H448-H459
2. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
3. Boswell-Smith V., Spina D., and Page C.P. Phosphodiesterase inhibitors. Br. J. Pharmacol. 147 Suppl 1 (2006) S252-S257
4. Budzyn K., Marley P.D., and Sobey C.G. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol. Sci. 27 (2006) 97-104
5. Callera G.E., Yeh E., Tostes R.C., Caperuto L.C., Carvalho C.R., and Bendhack L.M. Changes in the vascular β-adrenoceptor-activated signalling pathway in 2Kidney-1Clip hypertensive rats. Br. J. Pharmacol. 141 (2004) 1151-1158
6. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
7. Eckly-Michel A., Martin V., and Lugnier C. Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation. Br. J. Pharmacol. 122 (1997) 158-164
8. Eto M., Kitazawa T., Yazawa M., Mukai H., Ono Y., and Brautigan D.L. Histamine-induced vasoconstriction involves phosphorylation of a specific inhibitor protein for myosin phosphatase by protein kinase C α and δ isoforms. J. Biol. Chem. 276 (2001) 29,072-29,078
9. + channel blockers on β-adrenoceptor-mediated vasorelaxation of rat mesenteric artery. J. Cardiovasc. Pharmacol. 29 (1997) 515-519
10. + channels in dobutamine-induced relaxation in rat mesenteric artery. Clin. Exp. Pharmacol. Physiol. 25 (1998) 405-411
11. + channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc. Res. 57 (2003) 824-833
12. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., and Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol. Pharmacol. 57 (2000) 976-983
13. + channels in vascular smooth muscle cells. J. Smooth Muscle Res. 44 (2008) 65-81
14. Lai A., and Frishman W.H. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol. Rev. 13 (2005) 285-292
15. Lee D.L., Webb R.C., and Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44 (2004) 796-799
16. Liu C.Q., Leung F.P., Wong S.L., Wong W.T., Lau C.W., Lu L., Yao X., Yao T., and Huang Y. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem. Pharmacol. 78 (2009) 374-381
17. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
18. DR current in cerebral arteries requires an intact actin cytoskeleton. Am. J. Physiol. Heart Circ. Physiol. 296 (2009) H917-H926
19. Matsumoto T., Kobayashi T., and Kamata K. Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H283-H291
20. Matsumoto T., Kobayashi T., and Kamata K. Phosphodiesterases in the vascular system. J. Smooth Muscle Res. 39 (2003) 67-86
21. Mochida H., Takagi M., Inoue H., Noto T., Yano K., Fujishige K., Sasaki T., Yuasa K., Kotera J., Omori K., and Kikkawa K. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur. J. Pharmacol. 456 (2002) 91-98
22. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ. Res. 100 (2007) 309-327
23. Rose R.J., Liu H., Palmer D., and Maurice D.H. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br. J. Pharmacol. 122 (1997) 233-240
24. Sakurada S., Okamoto H., Takuwa N., Sugimoto N., and Takuwa Y. Rho activation in excitatory agonist-stimulated vascular smooth muscle. Am. J. Physiol. Cell. Physiol. 281 (2001) C571-C578
25. Shiga N., Hirano K., Hirano M., Nishimura J., Nawata H., and Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ. Res. 96 (2005) 1014-1021
26. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 39 (2002) 319-327
27. 2+ exchanger to pinacidil-induced relaxation in the rat mesenteric artery. Br. J. Pharmacol. 138 (2003) 453-460
28. 2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem. J. 389 (2005) 763-774
29. 2α mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ. Res. 104 (2009) 228-235
30. Yang Y., Shi Y., Guo S., Zhang S., Cui N., Shi W., Zhu D., and Jiang C. PKA-dependent activation of the vascular smooth muscle isoform of KATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance artery. Biochim. Biophys. Acta 1778 (2008) 88-96